Risultati di ricerca - Portale di modelli di dati medici (MDM-Portal)

Eligibility Breast Neoplasm NCT00573495

- 20/09/21 - 1 modulo, 2 itemgroups, 12 elementi, 1 linguaggio

Itemgroups: Inclusion Criteria, Exclusion Criteria

Multipeptide Vaccine for Advanced Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00573495

Eligibility Breast Cancer NCT00875238

- 20/09/21 - 1 modulo, 1 ItemGroup, 19 elementi, 1 linguaggio

ItemGroup: Criteria

Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab; ODM derived from: https://clinicaltrials.gov/show/NCT00875238

Eligibility Breast Cancer NCT00873808

- 20/09/21 - 1 modulo, 1 ItemGroup, 16 elementi, 1 linguaggio

ItemGroup: Criteria

S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307; ODM derived from: https://clinicaltrials.gov/show/NCT00873808

Eligibility Breast Cancer NCT00873366

- 20/09/21 - 1 modulo, 1 ItemGroup, 21 elementi, 1 linguaggio

ItemGroup: Criteria

Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00873366

Topotecan (HycamtinTM) with Carboplatin as First-Line Chemotherapy in Patients with Ovarian Cancer; 104864/612 - Baseline

- 17/09/21 - 1 modulo, 19 itemgroups, 80 elementi, 1 linguaggio

Itemgroups: Administrative documentation, Assessment Date, Demography, Menopausal Status, Medical History, Symptoms, Study Start Date, Concomitant Agent, ECOG performance status, Personal history of malignant neoplasm, unspecified, Ovarian Carcinoma, Histology, Ovarian Carcinoma, Operative Surgical Procedures, Tumor stage, Tumor Markers, Physical Examination, Lower abdomen, X-Ray Computed Tomography, Plain x-ray, Electrocardiography, Questionnaires, Quality of life, Receptor

Study ID: 104864/612 Clinical Study ID: 104864/612 Study Title: A Prospective, Open Label Phase II Study to Evaluate the Efficacy and Safety of Topotecan (HycamtinTM) in Combination with Carboplatin as First-line Chemotherapy in Patients with Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: HycamtinTM Study Indication: Ovarian Cancer

Eligibility Metastatic Breast Cancer NCT00864175

- 17/09/21 - 1 modulo, 2 itemgroups, 10 elementi, 1 linguaggio

Itemgroups: Inclusion Criteria, Exclusion Criteria

Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00864175

Effects of Low-fat and high-fat meals on the Pharmacokinetics of Lapatinib in ErB2+ Breast Cancer patients, NCT00821054 - Logs and Repeats

- 17/09/21 - 1 modulo, 3 itemgroups, 17 elementi, 1 linguaggio

Itemgroups: Administrative Data, Date of Visit/Assessment, Adverse Event/concomitant medication/repeat evaluation

Study ID: 111582 Clinical Study ID: 111582 Study Title: An Open Label Study to Examine the Effects of Low-fat and High-fat Meals on the Pharmacokinetics of Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00821054 https://clinicaltrials.gov/ct2/show/NCT00821054 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Lapatinib Trade Name: N/A Study Indication: Neoplasms, Breast The study consists of a screening, four study visits at day-1, week 1, 2 and 3 and a follow-up visit. This document contains the logs and repeats.

Eligibility Breast Cancer NCT00354302

- 02/09/21 - 1 modulo, 1 ItemGroup, 20 elementi, 1 linguaggio

ItemGroup: Criteria

Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial CAN-NCIC-MA27; ODM derived from: https://clinicaltrials.gov/show/NCT00354302

Eligibility Breast Cancer NCT00899288

- 02/09/21 - 1 modulo, 1 ItemGroup, 19 elementi, 1 linguaggio

ItemGroup: Criteria

Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98; ODM derived from: https://clinicaltrials.gov/show/NCT00899288

Lapatinib + Topotecan or + Capecitabine in Recurrent Brain Metastases from Breast Cancer; NCT00437073 - Log

- 26/04/21 - 1 modulo, 9 itemgroups, 117 elementi, 1 linguaggio

Itemgroups: Date of visit, Assessment Date, Event Log, Status, Non-serious Adverse Event, Serious Adverse Event, Concomitant Agent, Concomitant Agent, Adrenal Cortex Hormones, Blood product; Supportive care, Collection of blood specimen for laboratory procedure, Pharmacogenetic Test, Informed Consent, Pharmacogenetic Test, Informed Consent, Withdraw (activity)

Study ID: 107671 Clinical Study ID: 107671 Study Title: EGF107671 – A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radiotherapy Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00437073 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: N/A Trade Name: capecitabine, topotecan, lapatinib Study Indication: Neoplasms, Breast; Recurrent Brain Metastases